IL-8 production by peripheral blood mononuclear cells in nephrotic patients  by Garin, Eduardo H. et al.
Kidney International, Vol. 45 (1994), PP. 1311—1317
IL-8 production by peripheral blood mononuclear cells in
nephrotic patients
EDUARDO H. GARIN, D. KAY BLANCHARD, Koui MATSUSHIMA, and JULIE Y. DJEU
Nephrology Division, Department of Pediatrics, University of South Florida and H. Lee Moffitt Cancer Center, Tampa, Florida, and
National Cancer Institute, Frederick, Maryland, USA
IL-S production by peripheral blood mononuclear cells in nephrotlc
patients. We studied the interleukin 8 (IL-8) gene expression by
peripheral blood mononuclear cells (PBMC) and the IL-8 serum con-
centration in patients with idiopathic minimal lesion nephrotic syn-
drome (IMLNS) and other glomerulopathies. PBMC from eight of the
nine (IMLNS) patients in relapse demonstrated the presence of IL-8
mRNA. All three IMLNS patients in remission (P = 0.0026 when
compared to patients in relapse) and the two patients with nephrotic
syndrome with other glomerulopathies failed to elicit an IL-8 mRNA
response. Eleven of the 12 IMLNS patients in relapse showed IL-8
serum concentration above the level of detection. Only one of the seven
patients in remission had detectable serum levels of IL-8 (P = 0.0033
when compared to levels from IMLNS patients in relapse). IL-8 serum
levels were not detectable in three patients with nephrotic syndrome
and other glomerulopathies. Supernatants of PBMC cultures from
IMLNS patients in relapse increased the 35sulfate uptake by rat GBM.
This effect was abolished by the addition of anti-IL-8 neutralizing
antibody to the culture media and reproduced by the addition to the
media of IL-8 in concentrations found in the serum of IMLNS patients
in relapse. Finally, the effect of IL-8 on the 35sulfate turnover of the
glomerular basement membrane (GBM) sulfated compounds was eval-
uated in vitro. A significant decrease in the percentage of residual
35sulfate incorporated in the GBM (41 5, mean SEM) was observed
in cultures treated with IL-8 as compared to those that were not treated
with IL-8 (58 8, P < 0.01). Because IL-8 affects the metabolism of
GBM compounds that may play a role in glomerular permeability, this
lymphokine may have a potential pathogenic role in the proteinuria of
IMLNS.
Cytokines are hormone-like proteins produced by lympho-
cytes and monocytes that regulate the function of the immune
system. Cytokines are thought to play a role in the pathogenesis
of the idiopathic minimal lesion nephrotic syndrome (IMLNS)
[1]. Soluble products of peripheral blood mononuclear cells
(PBMC) may mediate the increased glomerular permeability to
plasma proteins. Circulating factors and supernatants from
IMLNS PBMC cultures when injected into the renal artery
have been shown to increase glomerular permeability to albu-
min [2] and to decrease the cationic stains of the capillary wall
[3].
Interleukin 8 (IL-8) is a cytokine originally purified from the
supernatant of human monocytes stimulated with lipopolysac-
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charide [4] but also known to be secreted by lymphocytes,
endothelial, and tubular cells. IL-8 was primarily thought to be
a neutrophil chemotactic factor. Subsequently, it has been
shown to activate neutrophil function and may serve as a
secondary mediator of inflammation. Recently, from a variety
of recombinant human cytokines tested, we and others have
found that IL-8 could alter the metabolism of the rat glomerular
basement membrane (GBM) sulfated compounds (unpublished
data) [5]. Because this in vitro finding may have pathogenic
significance in patients with IMLNS, we measured the plasma
concentration of IL-8 and assessed the capability of IL-8
production by PBMC of IMLNS patients at different stages of
development of the nephrotic syndrome.
Methods
Patients
Twenty-four patients with IMLNS defined by the Interna-
tional Study of Kidney Disease in Children [6] and four patients
with nephrotic syndrome and other glomerulopathies were
included in the study. Fifteen were males and thirteen were
females. Their ages ranged from three to 20 years with a median
age of 10 years.
Patients with ILMNS were studied in remission and in
relapse. Remission was defined as serum albumin within normal
limits and normal urinary protein excretion (trace or negative
by Albustix® or <5 mglm2/hour). Patients were considered in
relapse if massive proteinuria (3+ by Albustix or >50 mg/kg!
day) and a low serum albumin level (< 25 g/liter) were present.
Detection of circulating interleukin 8
The presence of IL.8 in serum samples of patients with
IMLNS and other glomerulopathies was measured by radioim-
munoassay using a commercially available kit (R and D Sys-
tems Inc., Minneapolis, Minnesota, USA). All samples were
studied in duplicate.
Northern blot analysis
To detect the presence of mRNA for IL-8, Northern blot
analysis was performed on PBMC collected by Ficoll Hypaque
density gradient centrifugation of heparinized whole blood [7]
from nine patients with IMLNS in relapse, three patients in
remission, and two patients with other glomerulopathies (focal
segmental glomerulosclerosis and membranous nephropathy)
immediately after PBMC cells were collected. In four of the
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same patients the mRNA expression for IL-8 was also studied
after 20 hours of incubation in RPMI 1640 medium.
Total cellular RNA was isolated according to the method of
Chomczynski and Sacchi [81. Twenty microgram samples of
RNA were fractionated on a 0.8% agarose gel, transferred to
Nytran filter paper and then stained with methylene blue-
acetate to determine presence and integrity of transferred RNA.
Hybridization was performed using a random-primed IL-8
cDNA probe labeled with dCTP-32P [9].
Effect of anti-IL-8 antibody on PBMC mediated increase in
35sulfate uptake by rat glomerular basement membrane
(GBM)
Glomeruli from Sprague-Dawley rats (100 to 350 g) (Charles
River, Wilmington, Massachusetts, USA) were isolated by the
method described by Fong and Drummond [10]. At the end of
the procedure, a drop of the preparation on a glass slide was
examined for purity by counting and expressing as a percentage
of the total number of glomeruli and nonglomerular fragments.
Preparations that were more than 5% contaminated with tubular
fragments were discarded.
Glomeruli obtained from each rat were suspended in 6 ml of
Basal Medium Eagle (BME, without sulfate, Catalog no: 424—
1300, Grand Island Biological Company, New York, New
York, USA) and divided into three aliquots. One was cultured
with 3 ml of supernatants from PBMC cultures from IMLNS
patients in relapse, another was cultured with 3 ml of same
supernatant but with the addition of 40 /Lg/ml of anti-human
IL-8 neutralizing IgG antibody (Rand D Systems Inc.), and 3 ml
of BME was added to the third aliquot. This sample served as
the control.
The culture medium was supplemented with 200 mrs glu-
tamine, 100 lU/mi penicillin, 100 j.g/ml streptomycin, 10%
decomplemented fetal calf serum, and 80 pCi of 35sulfate
(carrier free; New England Nuclear, Boston, Massachusetts,
USA). Glomeruli were incubated at 35°C in Petri dishes (50 x
50 mm) in a humidified atmosphere of 5% CO2. Twenty-four
hours later, samples were centrifuged, supernatant discarded
and pellet lyophilized. The pellet was kept at —70°C until GBM
was isolated.
Isolation of the GBM
GBM was prepared from lyophilized, isolated glomeruli by
the method of Meezan et a! [11] with minor modifications. The
washed precipitate was dried and resuspended in Atomlight
(New England Nuclear); radioactivity was counted for one
minute in a Beckman liquid scintillation counter. Results were
expressed in counts per minutes (cpm) per milligram of dry
glomerular weight.
Effect of recombinant human monocyte derived IL-8 on
35sulfate uptake by rat GBM
Glomeruli obtained from each rat were divided into two
aliquots. IL-8 was added to one and the other was cultured
alone. Two concentrations (200 and 10.000 pg/mI) were used.
Samples, after the addition of 80 pCi 35sulfate, were incubated
for 24 hours as previously described. Glomeruli were lyophi-
lized, GBM isolated, and radioactivity counted.
Effect of IL-8 on the 35sulfate turnover of GBM sulfated
compounds
Glomeruli obtained from each rat were divided into four
aliquots. Glomeruli were incubated in 5 ml of BME supple-
mented with 80 pCi of 35sulIate. Recombinant human IL-8 (200
ng/ml) was added to two of the four aliquots.
After 24 hours of incubation, samples were centrifuged,
supernatants discarded and pellet washed twice and resus-
pended in the same culture medium but without the radioactive
sulfate. Once again IL-8 (200 nglml) was added to the same
previous cultures that received IL-8, but 1 m of MgSO4 was
added to one of the cultures supplemented with IL-8 and to one
of the cultures which did not have IL-8. All samples were
incubated for 12 more hours.
At the end of incubation the samples were centrifuged, the
supernatants were collected, and the pellet was lyophilized and
kept at —35°C until the GBM was isolated. Radioactivity was
counted on isolated GBM. Results were expressed in cpm per
milligram of dry glomerular weight.
Statistics
Statistical analysis was performed using Fisher exact test,
Wilcoxon matched-pairs signed-rank test, Friedman analysis of
variance for ranks with the family-wise error maintained at 0.05
with the use of HoIm's stepdown multiple comparison proce-
dure, and 2 x 2 repeated measures analysis of variance.
Results
Figure 1 depicts the IL-8 serum concentration in IMLNS
patients in relapse and in remission. Eleven of the 12 patients
whose IL-8 serum concentration was measured during relapse
showed values above the level of detection. Only one of the
seven patients studied during remission had a detectable IL-8
serum concentration (P < 0.0033 as compared to relapse
patients). This patient went into relapse one week later. All
others remained in remission for at least three months after IL-8
was measured. IL-8 serum levels were not detectable in three
patients with nephrotic syndrome associated with other glom-
erulopathies (data not shown).
The expression of the IL-8 gene by PBMC was studied in nine
IMLNS patients during relapse, three IMLNS patients during
remission, and two patients with other glomerulopathies (focal
glomeruloscierosis and membranous nephropathy; Fig. 2A).
Data were collected from two sets of experiments. Figure 2B
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Fig. 1. Serum IL-8 (pg/mi) in IMLNS patients in relapse and in
remission.
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Fig. 2A. Spontaneous IL-8 mRNA induction by lymphocytes from IMLNS patients in relapse and in remission. At 0 hour IL-8 specific mRNA
was detected by Northern blotting (see text). IMLNS patients are represented in relapse and in remission. Other depicts patients with
glomerulopathies other than IMLNS. Control shows results of lymphocytes from a healthy adult. B. Methylene blue-acetate stained filter of 20 sg
of total RNA extracted from patients' PBMC and a normal control. The 28s and l8s ribosomal bands are shown.
shows the methylene blue-acetate stained Nytran filters after
loading each lane with 20 g of total RNA extracted from
patient's PBMC. The 28s and 18s ribosomal bands from all the
lanes verified that comparable amounts of total RNA were
loaded for each lane. PBMC from eight of the nine patients in
relapse demonstrated the IL-8 mRNA. The only (MFF) patient
who had a weak reaction at 0 hour showed a strong mRNA
expression after 24 hours of incubation. All three patients in
remission failed to elicit an IL-8 mRNA response at 0 hour (P =
0.0026as compared to IL-8 mRNA response of IMLNS patients
in relapse). In the two patients with nephrotic syndrome asso-
ciated with other glomerulopathies (CS and MF) no IL-8 and
mRNA response was detected.
The spontaneous IL-8 mRNA induction at 0 and 20 hours by
S 
Ip
. 
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Fig. 3A. Spontaneous IL-8 mRNA inductions at 0 and 20 hours by lymphocytes from IMLNS patients in remission (M1G), in relapse (MG, MFF)
and other glomerulopathy (MF). B. Methylene blue-acetate stained filter of 20 sg of total RNA extracted from patients' PBMC, The 28s and 18s
ribosomal bands are shown.
PBMC from IMLNS patients in remission (MIG), in relapse
(MG and MFF), and another glomerulopathy (MF) is shown in
Figure 3A. Figure 3B shows the methylene blue-acetate stained
filter of 20 j.g of total RNA extracted from PBMC of same
patients. Figure 3 demonstrates that comparable amounts of
total RNA were loaded in each lane. Only the two IMLNS
patients in relapse demonstrated the presence of IL-8 mRNA
after 20 hours of incubation.
The effect of two different concentrations of human mono-
cyte derived IL-8 in 35sulfate incorporation by rat GBM is
depicted in Table 1. At both concentrations, the 35sulfate
uptake in rat GBM was significantly higher when glomeruli
were cultured with IL-8 than when glomeruli were cultured
alone.
The effect of anti-IL-8 neutralizing antibody on supematant
PBMC cultures mediated increase 35sulfate uptake in rat GBM
is shown in Table 2. The 35sulfate incorporation in rat GBM was
significantly higher when glomeruli were cultured with super-
natant from nine IMLNS patients in relapse (800 229 cpmlmg
dry glomerular weight; mean SEM) than when glomeruli were
cultured with supernatants from the same patients and the
addition of anti-IL-8 antibody (400 91 cpm/mg; mean sEM;
P = 0.009) or glomeruli were cultured alone (442 94cpm/mg;
mean SEM; P = 0.009). No significant differences in "sulfate
uptake were observed when glomeruli alone cultures were
compared to glomeruli incubated with supematant from
IMLNS patients and the addition of anti-IL-8 antibody (P =
0.48).
The effect of IL-8 on the "sulfate turnover of GBM sulfated
compounds is shown in Table 3. "Sulfate incorporation was
significantly higher when glomeruli were cultured with the
addition of IL-8 (413 43 cpm/mg dry glomerular weight; mean
SEM) than it was when glomeruli were cultured in medium
alone (314 39 cpm/mg mean SEM; P < 0.05). Furthermore,
the addition of 1 m of MgSO4 to the culture media was
associated with a significant decrease in 35sulfate uptake in
GBM of both IL-8 treated and medium alone cultures as
compared to the uptake observed in cultures without MgSO4 (P
<0.0005 and <0.001, respectively), confirming the effect of the
chase (nontagged) sulfate molecule in the reincorporation of the
radiolabeled sulfate into the GBM sulfated compound. Finally,
the percentage of residual "sulfate incorporated in the GBM
after 12 hours of incubation with MgSO4 were 41 5 (mean
sEM) for cultures stimulated with IL-8 and 58 8 for glomeruli
cultured in the absence of IL-8 (P < 0.01), suggesting a higher
35sulfate turnover in the IL-8 treated cultures. Moreover, when
the same data were analyzed using F test for interaction in a 2
x 2 repeated measures analysis of variance, once again there
was a significant difference between the changes observed after
Mg was added to the culture media in both experimental
conditions (F = 9.35; P = 0.012).
A
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Fig. 3. Continued
Discussion
Our data show that IL-8 serum concentrations are increased
in IMLNS patients in relapse. All but one of the patients in
remission had levels not detectable by the radioimmunoassay.
However, one week later this patient was found to have mild
edema, proteinuria, and low serum albumin, indicating that the
increased IL-8 serum concentration had preceded the develop-
ment of proteinuria. Furthermore, the elevated serum levels
seem to be restricted to IMLNS patients since the three patients
with proteinuria associated with other glomerulopathies had
undetectable serum levels of IL-8.
IL-S is secreted by monocytes or lymphocytes [121 and other
nonimmune types of human cells. These include proximal and
distal tubular [13] and endothelial cells [14]. In this study, we
present evidence that PBMC from IMLNS patients in relapse
can express and secrete IL-8. This increase release of IL-8 by
PBMC could cause, at least in part, the elevated IL-S serum
levels observed in these patients.
The reason for the spontaneous increase in IL-8 production
by PBMC in these patients is not known. It does not seem to be
secondary to the nephrotic state, since patients with other types
of nephrotic syndrome did not have detectable IL-8 in their
serum. Most nephrotic patients' relapses are preceded by a
respiratory tract infection [151. This perhaps triggers the gene
expression for IL-S. However, this hypothesis cannot be con-
firmed because no data are available on the effect of viral
infections on PBMC IL-8 production.
An unexpected finding in this study was the presence of
mRNA for IL-8 after PBMC from IMLNS patients in relapse
were incubated for 20 hours. In the original studies on IL-8
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Table 1. "Sulfate uptake by GBM after incubation of glomeruli with
two concentrations of human, monocyte-derived IL-8
(A) Glomeruli + IL-8 (B) Glomeruli alone
(a) IL-8 200 pg/rnla 617
1117
1242
1962
1870
2035
1216
833
854
379
1095
698
1707
1552
1435
732
504
446
X±SEM 1305±176 948±170
(A') Glomeruli + IL-8 (B') Glomeruli alone
(b) IL-8 10,000 pg/rn/b 2077
490
919
923
331
978
3072
1500
838
789
224
466
836
357
784
1265
1051
698
X SEM 1236 287 719 110
"Sulfate uptake by rat GBM (cpm/mg dry glomerular weight)a A vs. B, P = 0.009
b A' vs. B', P = 0.034
Table 2. Effect of anti-IL-8 neutralizing antibody on PBMC mediated
increased "sulfate uptake by rat GBM
(A) Glomeruli
and PBMC
(B) Glomeruli and
PBMC and anti-
IL-8
(C) Glomeruli
alone
806 708 532
985 874 909
1446 342 702
2253 398 496
650 554 630
211 50 130
142 115 124
305 202 179
406 367 272
X SEM 800 229 400 91 442 94
35Sulfate uptake by rat GBM (cpm/mg dry glomerular weight).
X,2 = 13.8; P < 0.01.
A vs. B, P = 0.009; A vs. C, P = 0.009; B vs. C, P = 0.48.
secretion, when normal monocytes were stimulated with LPS,
the mRNA IL-8 production was shut down after a few hours
despite persistence of the stimulus in the culture media [4]. In
our patients, the gene associated with the increased production
of mRNA for IL-8 did not down-regulate after 20 hours in
culture, despite the absence of a known stimulus for IL-8
secretion of IL-8 and its increased serum concentration.
There are scarce data on serum concentration of lymphokines
in patients with nephrotic syndrome. In a group of patients with
IMLNS, membranoproliferative glomerulopathy and diabetic
nephropathy, Suranyi et al found that only tumor necrosis
factor (TNF) plasma concentrations were elevated with respect
to normal controls. Plasma levels of IL-i, IL-2 and interferons
(IFN A and B) were not different than those observed in normal
Table 3. 35Sulfate GBM uptake of glomeruli after cold chase
A
Glomeruli +
IL-8
B
Glomeruli ÷
IL-8 + MgSO4
C
Glomeruli
alone
D
Glomeruli
alone + MgSO4
602 288 302 100
331 117 282 141
174 129 141 120
523 195 219 69
324 89 447 170
562 120 427 141
417 224 363 437
447 269 214 182
427 204 316 219
532 97 569 192
207 65 176 110
Mean SEM
413 43 163 23 314 39 171 30
Glomeruli cultured in vitro in the presence (A) or absence (C) of IL-8
received a 12 hour pulse of "sulfate, as indicated in Methods, washed
with incubation media and incubated 12 hours in medium containing
unlabeled sulfate (1 mi MgSO4) without isotope (B and D). "Sulfate
GBM uptake (cpm/mg dry glomerular wt).
A vs. B, P < 0.0005; A vs. C, P = 0.023; C vs. D, P = 0.001.
controls [161. Moreover, renal tubular cells (one of the cells
known to produce IL-8) have been shown to express IL-8
mRNA and secrete antigenic IL-8 after stimulation with TNF
[13]. Perhaps TNF can also stimulate the production of IL-8 by
nephrotic PBMC.
Schnaper has determined that urine and serum from certain
nephrotic patients contain a suppressor lymphokine (soluble
immune response suppressor, SIRS) that inhibits antibody
production and delayed type hypersensitivity response in vivo
[17]. SIRS is produced by lymphocytes from patients with
IMLNS and other glomerulopathies, and also by patients with
other diseases who are not nephrotic. Furthermore, there is no
evidence to support a role for SIRS in mediating proteinuria in
nephrotic syndrome [17].
IL-2, IL-4 and SIRS are lymphokines found in the superna-
tant of PBMC cultures from patients with IMLNS and other
glomerulopathies [18—20]. Their role in the development of
proteinuna in IMLNS is unknown. Because all these lympho-
kines have been detected in patients with nephrotic syndrome
other than IMLNS, it is currently thought that they play a
secondary role, if any, in the increased glomerular permeability
to plasma proteins. Moreover, the significance of these in vitro
findings is questionable because, as in the case of IL-2, PBMC
from nephrotic patients have been shown to release IL-2 in the
culture media [20] but no increase in serum IL-8 concentration
has been reported [16].
Previous studies have hypothesized a role for lymphokines in
the proteinuria of IMLNS. In this report, we have shown that
PBMC from IMLNS patients in relapse express IL-8 mRNA
and that only IMLNS patients in relapse had an increased IL-8
serum concentration.
Furthermore, it seems that the previously described [21] in
vitro effect of the PBMC supernatants from IMLNS patients in
relapse is mediated, at least in part, by IL-8 because: (a) IL-8
was detected in the supernatants of the PBMC cultures from
these patients (data not shown); (b) this effect was abolished by
the addition of anti-IL-8 neutralizing antibody to the culture
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media; and (c) the addition of IL-8 to the culture media in
concentrations found in the serum of IMLNS patient in relapse
also increased the 35sulfate uptake by the GBM.
IL-8 found in the serum of the IMLNS patients in relapse
may play a role in the metabolism of glomerular sulfated
compounds since some IL-8 concentrations observed in the
serum of these patients were found in vitro to increase the
35sulfate uptake by rat GBM.
Finally, our in vitro experiments demonstrate that the aug-
mented GBM 35sulfate incorporation associated with IL-8 or
the supernatants from IMLNS PBMC cultures [22] is secondary
to an increased 35sulfate turnover of the GBM sulfated com-
pounds.
Polyanionic molecules in the GBM have been demonstrated
to restrict the passage of anionic serum proteins to the urinary
space by creating a charge selective barrier. This barrier seems
to play a major role in the glomerular permeability to serum
albumin in IMLNS. The nature of this electrostatic screen has
not been defined. Sulfate from heparan sulfate proteoglycan and
carboxylic groups from other molecules in the GBM might be
the key components. Although our results do not prove IL-8 to
be the pathogenetic lymphokine in IMLNS, these studies
demonstrating its presence in the serum of patients during
relapse and its effect on sulfate turnover in the glomerular
basement membrane, albeit indirect, suggest a possible rela-
tionship between IL-8 and increased glomerular permeability to
proteins. Further studies including the chronic infusion of IL-8
in the renal artery of experimental animals are required to
evaluate the potential of IL-8 as a proteinuria inducing lympho-
kine in IMLNS.
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